Gyrolab Spin Blog: assay-automation

High-throughput immunoassays underpin efficiency and productivity

Automation is being applied at many levels to power future development of recombinant therapeutic proteins, including screening for the most promising recombinant protein clones. Gregory Keil and co-authors at Merck & Co. have reviewed how this screening can be transformed by combining high-throughput screening methods, analytical techniques and automation to increase capacity, reduce manual operations and risk for error, lower operational costs, and shorten development timelines (see reference).

Accelerate every phase of your biopharma development

With the SLAS tagline ‘Come Transform Research’, we feel very much at home at this year’s Annual Conference and Exhibition, especially since we have come to launch a brand new system – Gyrolab xPlore, a smaller companion to Gyrolab xP workstation!

Guidelines for automating your LBAs for GxP

Thinking about automating ligand-binding assays (LBA) for a GxP environment? Assay automation can bring great value, including time and cost savings, better results, higher throughput, lower sample volume requirements and simplified proof-of-concept than manual methods. But each platform is different and brings its own protocols, recommendations and constraints. How does one even begin to define parameters that might be critical in validating assays on different types of platforms?

Automating Pharmacokinetic Bioanalysis at Nanoliter-Scale: Strategies for Development, Validation and Transfer

Using microfluidics platform to measure toxicology biomarkers with less sample

Do more with less. It’s an age-old concept, but this mantra especially resonates in today’s pre-clinical toxicology world as the pharmaceutical industry faces greater than ever challenges in getting lead compounds to market.